Cell Death Discovery (Oct 2021)

JWA suppresses proliferation in trastuzumab-resistant breast cancer by downregulating CDK12

  • Yan Liang,
  • Chao Qian,
  • Yinghong Xie,
  • Xiang Huang,
  • Junjie Chen,
  • Yanlin Ren,
  • Ziyi Fu,
  • Yongfei Li,
  • Tianyu Zeng,
  • Fan Yang,
  • Jianwei Zhou,
  • Wei Li,
  • Yongmei Yin,
  • Changqing Wang

DOI
https://doi.org/10.1038/s41420-021-00693-9
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 10

Abstract

Read online

Abstract Breast cancer is the most common cancer worldwide. JWA is a microtubule-associated protein that has been identified as a tumor suppressor, and its downregulation in tumors is an independent adverse prognostic factor. The objective of this study was to explore the expression, regulation, and mechanism of JWA in trastuzumab-resistant breast cancers. In this study, we found that JWA expression was lower in trastuzumab-resistant breast cancers than that in trastuzumab-sensitive breast cancers. Furthermore, it was confirmed that overexpression of JWA inhibited proliferation and promoted apoptosis in trastuzumab-resistant breast cancers both in vitro and in vivo. In addition, the low expression of JWA in trastuzumab-resistant breast cancers is associated with a poor prognosis. Combining RNA-sequence datasets and next-generation sequencing, it was found that JWA negatively regulated CDK12, and was involved in the G1-to-S transition of the cell cycle. It has been reported that CDK12 drives breast cancer initiation and induces trastuzumab resistance. Taken together, high expression of JWA could inhibit the growth of trastuzumab-resistant breast cancer, and JWA is a potential predictive marker for trastuzumab resistance. In addition, targeted therapy with JWA may be a novel therapeutic strategy to improve the survival rate of trastuzumab-resistant breast cancer.